Global BRAF
Kinase Inhibitors Market, by Drug (Vemurafenib, Dabrafenib, Lifirafenib,
and Encorafenib), by Indication (Metastatic Melanoma, Metastatic Lung Cancer,
and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies,
and Online Pharmacies), and by Region (North America, Latin America, Europe,
Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 924.8
Million in 2020 and is expected to exhibit a CAGR of 8.6% during the forecast
period (2020-2027), as highlighted in a new report published by Coherent Market
Insights.
BRAF kinase inhibitors Market -
Impact of Coronavirus (COVID-19) Pandemic
BRAF kinase inhibitor drugs are
required for cancer patients at advanced stage, which might be delayed due to
pandemic. During this COVID-19 pandemic, surgery, chemotherapy, and
immunotherapy of metastatic cancer patients are being postponed or even
cancelled. These BRAF kinase inhibitor drugs are a preferred treatment option,
as these drugs increase the survival rate of metastatic cancer patients in a
cost-effective way. In September 2019, according to the data published in NCBI,
the survival rate of a cancer patient increased by 67% who was under BRAF
inhibitor plus MEK inhibitor combination therapy within last 12 months. Also,
during this pandemic situation, demand for treatment of cancer patients with
COVID-19 infection has not reduced but the inadequate supplies of personal
protective equipment (PPE) for healthcare providers, limited hospital capacity,
including intensive care units (ICUs), and lack of point-of-care testing
devices have negatively impacted the treatment of cancer patients to some
extent.
The increasing number of product
approvals and launches, R&D activities, and collaboration and partnership
strategies adopted by key players are major factors, which are expected to
drive growth of the BRAF kinase inhibitors market during the forecast period.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/4240
The product approvals of advanced
BRAF kinase inhibitors from regulatory bodies in the market is expected to
contribute significantly to the BRAF kinase inhibitors market growth. For
instance, in July 2020, Roche announced that the U.S. Food and Drug
Administration (FDA) approved Tecentriq (atezolizumab) plus Cotellic
(cobimetinib) and Zelboraf (vemurafenib) for the treatment of BRAF V600
mutation-positive advanced melanoma patients. The safety profile observed in
the Tecentriq combination was consistent with the known safety profiles of
individual medicines.
New BRAF family kinase inhibitors
are being extensively researched to develop new drugs for the treatment of
metastatic cancers. Thus, rising R&D activities is expected to propel the
BRAF kinase inhibitors market growth over the forecast period. For instance,
BeiGene Limited has its experimental RAF family kinase inhibitor lifirafenib
(BGB-283) in the pipeline in Phase 1 trials for treatment of cancers including
BRAF gene mutations and KRAS/NRAS gene mutations. Furthermore, in May 2020, a
new study published in the Journal of Clinical Oncology reported that in a
Phase I trial, BeiGene's experimental RAF family kinase inhibitor lifirafenib
(BGB-283) demonstrated promising activity in patients with KRAS-mutated
non-small cell lung cancer and BRAF-mutated melanoma, thyroid cancer, and
ovarian cancer.
Browse 34 Market Data Tables and
32 Figures spread through 184 Pages and in-depth TOC on Global BRAF Kinase
Inhibitors Market, by Drug (Vemurafenib, Dabrafenib, Lifirafenib, and
Encorafenib), by Indication (Metastatic Melanoma, Metastatic Lung Cancer, and
Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and
Online Pharmacies), and By Region (North America, Latin America, Europe, Asia
Pacific, Middle East, and Africa) - Forecast to 2027"
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/braf-kinase-inhibitors-market-4240
The rising adoption of inorganic
growth strategies such as collaborations and partnerships by major companies is
expected to drive growth of the BRAF kinase inhibitors market. For instance, in
January 2015, Pierre Fabre and Array BioPharma Inc. (acquired by Pfizer Inc. in
July 2019) announced a collaboration to globally develop and commercialize
Array’s late-stage novel oncology products, binimetinib and encorafenib.
Binimetinib, a MEK inhibitor and encorafenib, a BRAF inhibitor, are currently
advancing in three global Phase 3 trials for melanoma and ovarian cancer.
Pierre Fabre has the exclusive rights to commercialize both products in all
other countries, including Europe, Asia, and Latin America.
Key Takeaways of the BRAF Kinase
Inhibitors Market:
The BRAF kinase inhibitors market
is expected to exhibit a CAGR of 8.6% during the forecast period (2020-2027),
owing to the increasing number of product approvals and launches by key players
Among drug type, the dabrafenib
segment is expected to hold a major revenue share in 2027, owing to the
increasing product launches of BRAF kinase inhibitors for treatment of
metastatic cancers. For instance, in May 2018, the U.S. Food and Drug
Administration approved dabrafenib (TAFINLAR) and trametinib (MEKINIST) manufactured
by Novartis Pharmaceuticals Corp. as a combination treatment for patients with
locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E
mutation.
Major players operating in the
BRAF kinase inhibitors market include F. Hoffmann-La Roche AG, Novartis
International AG, and Pfizer, Inc.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/4240
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment